1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer : Biomarkers associated with outcomes from OPTIMIZE-1
(2025) In Cell Reports Medicine
- Contribution to journal › Article
- 2024
-
Mark
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1) : a single-arm, multicentre phase 1b/2 study
- Contribution to journal › Article